CONCERTA® (Methylphenidate Hydrochloride) as add-on Therapy in the Treatment of Adult Major Depressive Disorder.
Status:
Completed
Trial end date:
2006-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effects of the addition of CONCERTA®
(methylphenidate hydrochloride, a central nervous system (CNS) stimulant) or placebo in adult
outpatients with Major Depressive Disorder who are currently being treated with oral
antidepressant medication (selective serotonin reuptake inhibitors or selective norepinephine
reuptake inhibitors). The general symptoms of depression will be evaluated, as measured by
the Montgomery Asberg Depression Rating Score (MADRS) on fatigue, energy, and overall
severity of illness. The safety and tolerability of the CONCERTA® and antidepressant
combination therapy will also be assessed.